C
Halozyme Therapeutics, Inc.
HALO
$38.63
$0.170.44%
C
Hold
4/18/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 4/18/2023 due to a major decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 4/18/2023 due to a major decline in the total return index and volatility index.
C
Hold
3/16/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 3/16/2023 due to a large decline in the total return index, growth index and volatility index. Total revenue declined 13.15% from $208.98M to $181.5M, EBIT declined 9.3% from $83.69M to $75.91M, and earnings per share declined from $0.44 to $0.4231.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 3/16/2023 due to a large decline in the total return index, growth index and volatility index. Total revenue declined 13.15% from $208.98M to $181.5M, EBIT declined 9.3% from $83.69M to $75.91M, and earnings per share declined from $0.44 to $0.4231.
B
Buy
2/1/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index and volatility index.
B
Buy
12/8/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 12/8/2022 due to a major increase in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 12/8/2022 due to a major increase in the total return index and volatility index.
B
Buy
12/2/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 12/2/2022 due to a large increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 12/2/2022 due to a large increase in the total return index.
C
Hold
11/11/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/11/2022 due to a significant decline in the total return index, valuation index and solvency index. Debt to equity increased from 4.26 to 15.53.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/11/2022 due to a significant decline in the total return index, valuation index and solvency index. Debt to equity increased from 4.26 to 15.53.
B
Buy
8/18/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 8/18/2022 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 8.06 to 2, earnings per share declined from $0.43 to $0.16, and EBIT declined 54.99% from $75.67M to $34.06M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 8/18/2022 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 8.06 to 2, earnings per share declined from $0.43 to $0.16, and EBIT declined 54.99% from $75.67M to $34.06M.
B
Buy
7/28/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 7/28/2022 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 33.85% from $56.53M to $75.67M, debt to equity declined from 4.46 to 3.38, and total revenue increased 14.98% from $102M to $117.28M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 7/28/2022 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 33.85% from $56.53M to $75.67M, debt to equity declined from 4.46 to 3.38, and total revenue increased 14.98% from $102M to $117.28M.
B
Buy
5/9/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 5/9/2022 due to an increase in the efficiency index, volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 5/9/2022 due to an increase in the efficiency index, volatility index and total return index.
C
Hold
2/17/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index, total return index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy
2/2/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 2/2/2022 due to an increase in the total return index, valuation index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 2/2/2022 due to an increase in the total return index, valuation index and efficiency index.
C
Hold
1/18/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 1/18/2022 due to a decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 1/18/2022 due to a decline in the total return index and volatility index.
B
Buy
11/4/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/4/2021 due to a substantial increase in the valuation index, efficiency index and solvency index. Net income increased 136.82% from $91.46M to $216.59M, debt to equity declined from 7.32 to 3.12, and total capital increased 16.25% from $998.51M to $1.16B.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/4/2021 due to a substantial increase in the valuation index, efficiency index and solvency index. Net income increased 136.82% from $91.46M to $216.59M, debt to equity declined from 7.32 to 3.12, and total capital increased 16.25% from $998.51M to $1.16B.
C
Hold
10/14/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/14/2021 due to a decline in the volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/14/2021 due to a decline in the volatility index and total return index.
B
Buy
9/29/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/29/2021 due to an increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/29/2021 due to an increase in the total return index.
C
Hold
8/12/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 8/12/2021 due to a noticeable increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.19 to $0.62, EBIT increased 83.4% from $50.74M to $93.05M, and total revenue increased 53.28% from $89.02M to $136.46M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 8/12/2021 due to a noticeable increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.19 to $0.62, EBIT increased 83.4% from $50.74M to $93.05M, and total revenue increased 53.28% from $89.02M to $136.46M.
C
Hold
5/26/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 5/26/2021 due to a major decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 5/26/2021 due to a major decline in the total return index and volatility index.
C
Hold
5/11/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 70.19% from $553.14M to $941.37M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 70.19% from $553.14M to $941.37M.
C
Hold
3/16/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 3/16/2021 due to a major decline in the growth index, total return index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 3/16/2021 due to a major decline in the growth index, total return index and efficiency index.
C
Hold
1/5/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 1/5/2021 due to a noticeable increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 1/5/2021 due to a noticeable increase in the total return index.
C
Hold
12/21/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 12/21/2020 due to a decline in the total return index, volatility index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 12/21/2020 due to a decline in the total return index, volatility index and valuation index.
C
Hold
12/3/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 12/3/2020 due to a large increase in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 12/3/2020 due to a large increase in the total return index and volatility index.
C
Hold
11/18/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 11/18/2020 due to a large decline in the total return index, valuation index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 11/18/2020 due to a large decline in the total return index, valuation index and efficiency index.
C
Hold
11/3/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from D+ on 11/3/2020 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 84.7% from $3.29M to $6.08M, net income increased 40.24% from $25.82M to $36.21M, and EBIT increased 36.35% from $29.56M to $40.3M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from D+ on 11/3/2020 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 84.7% from $3.29M to $6.08M, net income increased 40.24% from $25.82M to $36.21M, and EBIT increased 36.35% from $29.56M to $40.3M.
D
Sell
4/2/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/2/2020 due to an increase in the total return index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/2/2020 due to an increase in the total return index and valuation index.
D
Sell
3/17/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 3/17/2020 due to a significant decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.27 to 4.42.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 3/17/2020 due to a significant decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.27 to 4.42.
D
Sell
2/19/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 2/19/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Total revenue increased 18.09% from $39.15M to $46.23M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 2/19/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Total revenue increased 18.09% from $39.15M to $46.23M.
D
Sell
8/7/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 8/7/2019 due to a large decline in the growth index. Earnings per share declined from $0.01 to -$0.1006, EBIT declined 571.24% from $2.97M to -$13.98M, and operating cash flow declined 460.26% from -$4.42M to -$24.79M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 8/7/2019 due to a large decline in the growth index. Earnings per share declined from $0.01 to -$0.1006, EBIT declined 571.24% from $2.97M to -$13.98M, and operating cash flow declined 460.26% from -$4.42M to -$24.79M.
D
Sell
8/5/2019Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 8/5/2019 due to an increase in the volatility index, solvency index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 8/5/2019 due to an increase in the volatility index, solvency index and efficiency index.
D
Sell
5/8/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 5/8/2019 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 142.29% from $10.46M to -$4.42M, total revenue declined 5.45% from $60.23M to $56.95M, and total capital declined 2.62% from $375.27M to $365.45M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 5/8/2019 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 142.29% from $10.46M to -$4.42M, total revenue declined 5.45% from $60.23M to $56.95M, and total capital declined 2.62% from $375.27M to $365.45M.
D
Sell
4/23/2019Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/23/2019 due to an increase in the total return index, volatility index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/23/2019 due to an increase in the total return index, volatility index and solvency index.
D
Sell
2/25/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 2/25/2019 due to a major decline in the efficiency index, valuation index and total return index. Total capital declined 2.83% from $386.2M to $375.27M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 2/25/2019 due to a major decline in the efficiency index, valuation index and total return index. Total capital declined 2.83% from $386.2M to $375.27M.
D
Sell
11/7/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 11/7/2018 due to a large decline in the valuation index, growth index and efficiency index. Total revenue declined 27.4% from $35.2M to $25.56M, EBIT declined 26.91% from -$20.07M to -$25.47M, and net income declined 21.65% from -$22.89M to -$27.85M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 11/7/2018 due to a large decline in the valuation index, growth index and efficiency index. Total revenue declined 27.4% from $35.2M to $25.56M, EBIT declined 26.91% from -$20.07M to -$25.47M, and net income declined 21.65% from -$22.89M to -$27.85M.
C
Hold
10/24/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 10/24/2018 due to a decline in the volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 10/24/2018 due to a decline in the volatility index and total return index.
C
Hold
9/20/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 9/20/2018 due to an increase in the volatility index, valuation index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 9/20/2018 due to an increase in the volatility index, valuation index and solvency index.
C
Hold
8/8/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C- from D+ on 8/8/2018 due to a major increase in the growth index, efficiency index and valuation index. Earnings per share increased from -$0.1925 to -$0.16, net income increased 16.63% from -$27.46M to -$22.89M, and EBIT increased 15.35% from -$23.71M to -$20.07M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C- from D+ on 8/8/2018 due to a major increase in the growth index, efficiency index and valuation index. Earnings per share increased from -$0.1925 to -$0.16, net income increased 16.63% from -$27.46M to -$22.89M, and EBIT increased 15.35% from -$23.71M to -$20.07M.
D
Sell
8/2/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 8/2/2018 due to a large decline in the total return index, volatility index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 8/2/2018 due to a large decline in the total return index, volatility index and solvency index.
C
Hold
5/14/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 5/14/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.8457 to -$0.1925, net income declined 122.17% from $123.88M to -$27.46M, and EBIT declined 118.83% from $125.93M to -$23.71M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 5/14/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.8457 to -$0.1925, net income declined 122.17% from $123.88M to -$27.46M, and EBIT declined 118.83% from $125.93M to -$23.71M.
C
Hold
5/10/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 5/10/2018 due to a noticeable increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 5/10/2018 due to a noticeable increase in the total return index.
C
Hold
4/25/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 4/25/2018 due to a large decline in the total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 4/25/2018 due to a large decline in the total return index.
C
Hold
2/21/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from D on 2/21/2018 due to a substantial increase in the total return index, efficiency index and valuation index. Net income increased 4,406.44% from $2.75M to $123.88M, and total capital increased 47.08% from $279.24M to $410.72M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from D on 2/21/2018 due to a substantial increase in the total return index, efficiency index and valuation index. Net income increased 4,406.44% from $2.75M to $123.88M, and total capital increased 47.08% from $279.24M to $410.72M.
D
Sell
5/11/2016Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D from D- on 5/11/2016 due to an increase in the efficiency index and total return index. Total capital increased 142.9% from $92.83M to $225.49M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D from D- on 5/11/2016 due to an increase in the efficiency index and total return index. Total capital increased 142.9% from $92.83M to $225.49M.
D
Sell
3/11/2016Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.95 to 2.25.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.95 to 2.25.
NASDAQ
04/26/2024 9:51AM Eastern
Quotes delayed
